1. Volume 16, Issue 9, Pages 1123-1132 (September 2015)
Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial 
Prof Sue M Moss, PhD, Christopher Wale, MSc, Robert Smith, PhD, Prof Andrew Evans, FRCR, Prof Howard Cuckle, DPhil, Prof Stephen W Duffy, MSc 
The Lancet Oncology 
Volume 16, Issue 9, Pages (September 2015)
DOI: /S (15)00128-X
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
PNL=prior notification list. NHSBSP=National Health Service Breast Screening Programme. NHSCR=National Health Service Central Register.
The Lancet Oncology  , DOI: ( /S (15)00128-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Nelson-Aalen estimate of cumulative breast cancer mortality (restricted to deaths from breast cancers diagnosed in the intervention phase)
The Lancet Oncology  , DOI: ( /S (15)00128-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3
Nelson-Aalen estimate of cumulative breast cancer mortality (all dates of diagnosis)
The Lancet Oncology  , DOI: ( /S (15)00128-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions

5. Figure 4
Rate ratio of breast cancer mortality in the intervention group, according to period of diagnosis of breast cancer
The Lancet Oncology  , DOI: ( /S (15)00128-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions

6. Figure 5
Cumulative incidence of in-situ and invasive breast cancer (A), in-situ breast cancer alone (B), or invasive breast cancer alone (C)
The Lancet Oncology  , DOI: ( /S (15)00128-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions